Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Benamran

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Urologic Oncology|May 30, 2020
External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter studyRomain Diamand, Marco Oderda, Simone Albisinni, et al.
World Journal of Urology|September 25, 2024
Transrectal versus transperineal prostate fusion biopsy: a pair-matched analysis to evaluate accuracy and complicationsMarco Oderda, Romain Diamand, Rawad Abou Zahr, et al.
European Urology Focus|March 20, 2024
Transperineal or Transrectal Magnetic Resonance Imaging-targeted Biopsy for Prostate Cancer DetectionRomain Diamand, Karsten Guenzel, Georges Mjaess, et al.
World Journal of Urology|April 30, 2022
Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomyAmandeep Arora, Ahmed S Zugail, Felipe Pugliesi, et al.
World Journal of Urology|May 15, 2024
The impact of prostate volume estimation on the risk-adapted biopsy decision based on prostate-specific antigen density and magnetic resonance imaging scoreArthur Baudewyns, Karsten Guenzel, Adam Halinski, et al.
World Journal of Urology|March 15, 2023
Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approachMichael Baboudjian, Alberto Breda, Thierry Roumeguère, et al.
European Urology Oncology|January 25, 2024
The Added Value of Side-specific Systematic Biopsy in Patients Diagnosed by Magnetic Resonance Imaging-targeted Prostate BiopsyHenri-Alexandre Bourgeno, Teddy Jabbour, Arthur Baudewyns, et al.
World Journal of Urology|June 12, 2024
External validation and comparison of magnetic resonance imaging-based risk prediction models for prostate biopsy stratificationRomain Diamand, Karsten Guenzel, Teddy Jabbour, et al.
Prostate Cancer and Prostatic Diseases|July 24, 2024
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesionsGeorges Mjaess, Laura Haddad, Teddy Jabbour, et al.
Nature Communications|February 21, 2026
Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancerMaryline Falquet, Hajar El Ahanidi, Alejandra Gomez-Cadena, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Urologic Oncology|May 30, 2020
External validation of the Briganti nomogram predicting lymph node invasion in patients with intermediate and high-risk prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies: A European multicenter studyRomain Diamand, Marco Oderda, Simone Albisinni, et al.
World Journal of Urology|September 25, 2024
Transrectal versus transperineal prostate fusion biopsy: a pair-matched analysis to evaluate accuracy and complicationsMarco Oderda, Romain Diamand, Rawad Abou Zahr, et al.
European Urology Focus|March 20, 2024
Transperineal or Transrectal Magnetic Resonance Imaging-targeted Biopsy for Prostate Cancer DetectionRomain Diamand, Karsten Guenzel, Georges Mjaess, et al.
World Journal of Urology|April 30, 2022
Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomyAmandeep Arora, Ahmed S Zugail, Felipe Pugliesi, et al.
World Journal of Urology|May 15, 2024
The impact of prostate volume estimation on the risk-adapted biopsy decision based on prostate-specific antigen density and magnetic resonance imaging scoreArthur Baudewyns, Karsten Guenzel, Adam Halinski, et al.
World Journal of Urology|March 15, 2023
Expanding inclusion criteria for active surveillance in intermediate-risk prostate cancer: a machine learning approachMichael Baboudjian, Alberto Breda, Thierry Roumeguère, et al.
European Urology Oncology|January 25, 2024
The Added Value of Side-specific Systematic Biopsy in Patients Diagnosed by Magnetic Resonance Imaging-targeted Prostate BiopsyHenri-Alexandre Bourgeno, Teddy Jabbour, Arthur Baudewyns, et al.
World Journal of Urology|June 12, 2024
External validation and comparison of magnetic resonance imaging-based risk prediction models for prostate biopsy stratificationRomain Diamand, Karsten Guenzel, Teddy Jabbour, et al.
Prostate Cancer and Prostatic Diseases|July 24, 2024
Refining clinically relevant cut-offs of prostate specific antigen density for risk stratification in patients with PI-RADS 3 lesionsGeorges Mjaess, Laura Haddad, Teddy Jabbour, et al.
Nature Communications|February 21, 2026
Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancerMaryline Falquet, Hajar El Ahanidi, Alejandra Gomez-Cadena, et al.
Pageof 6